Reading Room
This Reading Room provides practical synopses of articles by IPF experts and other distinguished authors. Each summary includes a link to the article abstract.
Antacid Therapy and Disease Outcomes in Idiopathic Pulmonary Fibrosis: A Pooled Analysis
Publication by:
Kreuter M, Wuyts W, Renzoni E, et al. Lancet Respir Med. 2016;4(5):381-389.
Faculty:
Marilyn K. Glassberg, MD
Professor of Medicine and Surgery
University of Miami Health System
Miami, Florida
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Publication by:
Richeldi L, Cottin V, du Bois RM, et al. Respir Med. 2016;113:74-79
Faculty:
A. Whitney W. Brown, MD
Director of Clinical Operations
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Fairfax, Virginia
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Publication by:
Noble PW, Albera C, Bradford WZ, et al. Eur Respir J. 2016;47(1):243-253.
Faculty:
A. Whitney W. Brown, MD
Director of Clinical Operations
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Fairfax, Virginia
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
Faculty
Timothy P. M. Whelan, MD
Associate Professor
Division of Pulmonary and Critical Care
Medical University of South Carolina
Charleston, South Carolina
Ten-year survival in patients with idiopathic pulmonary fibrosis after lung transplantation
Faculty
Timothy P. M. Whelan, MD
Associate Professor
Division of Pulmonary and Critical Care
Medical University of South Carolina
Charleston, South Carolina
TOLLIP, MUC5B and the Response to N-acetylcysteine Among Individuals with Idiopathic Pulmonary Fibrosis
Faculty
Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia
Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Faculty
Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia
Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis
Faculty
Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia
Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study
Faculty
Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia
A Phase 1b Study Of Placenta-Derived Mesenchymal Stromal Cells In Patients With Idiopathic Pulmonary Fibrosis
Faculty
Marilyn Glassberg, MD
Professor of Medicine and Surgery
Miller School of Medicine, University of Miami
Miami, Florida
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
Publication by the Idiopathic Pulmonary Fibrosis Clinical Research Network et al (N Engl J Med. 2012;366(21):1968-1977.)
Commentary by Kevin R. Flaherty, MD, MS, of the University of Michigan Health System
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.
Publication by Lee JS et al (Am J Respir Crit Care Med. 2011;184:1390-1394, 2911.)
Commentary by Glenn D. Rosen, MD, of Stanford University School of Medicine
The impact of rheumatological evaluation in the management of patients with interstitial lung disease
Publication by Castelino FV, et al (Rheumatology. 2011;50(3):489-493.)
Commentary by Imre Noth, MD, of the University of Chicago Hospitals and Clinics
Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT
Publication by Silva CI, et al (Radiology. 2008;246:288-297.)
Commentary by W. Richard Webb, MD, of the University of San Francisco
Pirfenidone in idiopathic pulmonary fibrosis
Publication by Taniguchi H, et al (Eur Resp J. 2010;35:821-829.)
Commentary by Glenn D. Rosen, MD, of Stanford University School of Medicine
Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer
Publication by Wang Y, et al (Am J Hum Genet. 2009;84:52-59.)
Commentary by Paul W. Noble, MD, of Duke University
Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis
Publication by Moeller A, et al (Am J Resp Crit Care Med. 2009;179:588-594.)
Commentary by Imre Noth, MD, of the University of Chicago
The prevalence of coronary artery disease in end-stage pulmonary disease: Is pulmonary fibrosis a risk factor?
Publication by Izbicki G, et al (Respiratory Medicine. 2009;103:1346-1349.)
Commentary by Steven A. Sahn, MD, of the Medical University of South Carolina
MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis
Publication by Rosas IO, et al (PLoS Med. 2008;5(4):e93.)
Commentary by Charlie Strange, MD, of the Medical University of South Carolina
